INTREPID establishes a statistically significant Phase 3 signal for dual IL-1α and IL-1β inhibition in hidradenitis suppurativa, with an eight-point absolute HiSCR75 advantage at week 16. Clinical differentiation against approved biologics requires full data…
The final GLOW analysis reports durable progression-free and overall-survival advantages for fixed-duration ibrutinib plus venetoclax over chlorambucil plus obinutuzumab in older or comorbid untreated chronic lymphocytic leukemia. The long follow-up strengthens the regimen’s internal…
The FDA approved AbbVie’s once-daily tavapadon, branded Juvmo, for adults with Parkinson’s disease with or without levodopa. The decision creates the first approved selective D1/D5 receptor agonist and is supported by three randomized Phase…
AbbVie’s investigational BCMAxCD3 bispecific etentamig met both dual primary endpoints in the 393-patient Phase III CERVINO trial. Objective response was 74.0% versus 45.7% with investigator-selected standard therapy, and progression-free survival favored etentamig with a…
Genmab and AbbVie clarified on July 23 that overall survival — the sole U.S. primary endpoint in Phase 3 EPCORE DLBCL-1 — was not met. The randomized trial had previously shown a progression-free-survival hazard…
The European Commission approved TEPKINLY (epcoritamab) in combination with lenalidomide and rituximab (R2) for adults with relapsed or refractory follicular lymphoma. The approval is supported by the Phase 3 EPCORE FL-1 trial, where TEPKINLY…
AbbVie will present 21 abstracts at EHA 2026 spanning multiple myeloma, DLBCL, follicular lymphoma, CLL, AML, and AL amyloidosis. The most important readout is etentamig (ABBV-383) in patients previously exposed to BCMA-directed therapies, a…
